Investing in early stage biotech companies calls for a lot of understanding in regard to the processes related to drug testing and approval, and so is a unique challenge. Clearly, there is a stage to invest with less risk once a drug has been approved and the revenue picture emerges. However, there is significantly more money made by taking positions early in companies with significant and clear potential. Although this involves more risk, a prudent selection out of all that is available, followed by diversifying the exposure of this at-risk-money between companies within this sector can lead to significant investment profits. In fact, for my own portfolio during 2013, I have regrets only about one biotech that I screened, bought...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|